TABLE 4.

Regression model controlling for systolic blood pressure and detectible serum lisinopril at week 52

	R 2	Week 52 SBP			Lisinopril
		Estimate	95% Conf. Limits	p‐Value	Estimate	95% Conf. Limits	p‐Value
LVMI (g/m2)	.1342	0.2636	[0.085, 0.442]	.004	‐0.5463	[−6.911, 5.818]	.864
PICP/CITP	.0237	0.3126	[−0.255, 0.88]	.275	8.603	[−11.628, 28.834]	.399
PICP	.0704	0.4603	[0.039, 0.881]	.032	4.9843	[−10.029, 19.998]	.509
CITP	.0057	0.0095	[−0.032, 0.051]	.653	‐0.1895	[−1.683, 1.304]	.801
MMP‐1/TIMP‐1	.1191	‐0.0002	[−0.001, 0]	.186	0.0139	[0, 0.027]	.043
MMP‐1	.0893	‐0.0371	[−0.089, 0.015]	.156	1.4337	[−0.411, 3.278]	.125
TIMP‐1	.0274	‐0.0235	[−0.54, 0.493]	.927	‐11.9787	[−30.375, 6.417]	.198
Ac‐SDKP	.1666	0.0148	[−0.025, 0.054]	.456	2.4915	[1.085, 3.898]	.001

Abbreviations: Ac‐SDKP, N‐acetyl‐seryl‐aspartyl‐lysyl‐proline; CITP, telopeptide of collagen type I; LVMI, Left ventricular mass‐Indexed; MMP‐1, matrix metalloproteinase‐1; PICP, type 1 procollagen C‐terminal propeptide; TIMP‐1, tissue inhibitor of metalloproteinases 1.